Loading...
Johnson & Johnson has reported strong earnings and raised its profit outlook for 2023. The company's medtech and pharmaceutical sales surged, leading to better-than-expected results. Johnson & Johnson's drugs business performed well and came in slightly ahead of expectations. The company recorded a $21 billion gain from its newer cancer treatments. The positive performance has prompted Johnson & Johnson to increase its annual profit forecast, banking on growing demand for its products. The healthcare-products firm Abbott also beat third-quarter estimates, despite a drop in sales of Covid-19 testing kits. Abbott's growth in medical devices for heart disease and diabetes contributed to its better-than-expected results. The midpoint of Abbott's earnings guidance for the year has been raised. Procter & Gamble is about to report its earnings, and expectations are high. Stay tuned for more updates.
Abbott Labs quarterly results beat estimates on growth in medical devices for heart disease and diabetes https://t.co/p3c5oVxMr0
Healthcare-products firm Abbott beat third-quarter estimates despite a drop in sales of Covid-19 testing kits. It raised the midpoint of earnings guidance for the year. https://t.co/pRJGHTQT53
P&G tops quarterly profit estimates on pricing boost, resilient demand https://t.co/qmCgPZMpmu https://t.co/Pp30vrXGcN
$PG (+1.9% pre) P&G tops earnings and sales estimates after hiking prices https://t.co/yqqQyQ5fy4
Proctor & Gamble $PG organic revenue up as higher pricing offset lower volume https://t.co/mo3fToJk4E https://t.co/A8wwJlvozK
Procter & Gamble is about to report earnings. Here's what to expect https://t.co/EBoKHVK8Z9
Johnson and Johnson RAISES ANNUAL PROFIT FORECAST ON STRONG CANCER DRUG DEMAND (Reuters) Johnson and Johnson on Tuesday raised its 2023 profit forecast, banking on growing demand for its newer cancer treatments such as Carvykti and Tecvayli and recorded a $21 billion gain from… https://t.co/ha7lZ0cGKs https://t.co/NcJlUUpIhr
$JNJ (+0.7% pre) Johnson & Johnson earnings top forecasts, shares jump, on new cancer drug boost - The Street https://t.co/YylwGB9I6g
Johnson & Johnson beats on earnings as medtech, pharmaceutical sales surge @CNBC https://t.co/xm1a8E52IM
Johnson & Johnson raises its 2023 revenue outlook as its drugs business came in slightly ahead of expectations https://t.co/ushiEsyiKS
J&J lifts profit outlook on strong demand for top-seller Stelara https://t.co/exXhuwW7qq https://t.co/YuNpFSa5U4
J&J raises annual profit forecast on anti-inflammatory drug demand https://t.co/CxkdgWNA6v by @Reuters
Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surge https://t.co/p96AJ5PBxY
Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surge https://t.co/HlRYVtk23J